Altre lingue Precision BioSciences, Inc.

Azioni

DTIL

US74019P2074

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
9,74 ^USD	-9,14%		-31,02%	-11,05%

16/04	Transcript : Precision BioSciences, Inc. - Special Call
16/04	Precision BioSciences, Inc. annuncia la restituzione di programmi e la conclusione della collaborazione con Prevail Therapeutics	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	16/04
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Precision BioSciences: Q4 Earnings Snapshot	27/03
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	27/03
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	27/03
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	20/03
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy	19/03
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506	07/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	04/03
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	01/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	01/03
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants	29/02
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness	14/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Precision BioSciences, Inc.

Azioni

DTIL

US74019P2074

Altre lingue

Filtri